YUMA REGIONAL MEDICAL CENTER
- Type
- Teaching hospital
- Where
- Yuma, AZ
- Medicare CCN
- 030013
- Received
- $273,477 in 40 records, 2024 ($18,092 general, $255,385 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: YUMA REGIONAL MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: YUMA REGIONAL MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: YUMA REGIONAL MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: YUMA REGIONAL MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: YUMA REGIONAL MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: Yuma Regional Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 19 | $18,092 |
| 2024 | Research payment | 21 | $255,385 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca UK Limited | 1 | $49,639 | 2024 |
| ABBVIE INC. | 2 | $48,086 | 2024 |
| Regeneron Pharmaceuticals, Inc. | 11 | $45,472 | 2024 |
| Novartis Pharmaceuticals Corporation | 1 | $44,237 | 2024 |
| AstraZeneca Pharmaceuticals LP | 3 | $33,547 | 2024 |
| Merck Sharp & Dohme LLC | 1 | $33,210 | 2024 |
| Smith+Nephew, Inc. | 3 | $4,947 | 2024 |
| AngioDynamics, Inc. | 6 | $4,498 | 2024 |
| Penumbra, Inc. | 1 | $2,000 | 2024 |
| Medtronic, Inc. | 1 | $1,958 | 2024 |
| Surmodics, Inc. | 3 | $1,943 | 2024 |
| Stryker Corporation | 3 | $1,153 | 2024 |
| Janssen Biotech, Inc. | 1 | $750 | 2024 |
| Aveo Pharmaceuticals, Inc. | 1 | $750 | 2024 |
| Siemens Medical Solutions USA, Inc. | 1 | $750 | 2024 |
| Abbott Laboratories | 1 | $534 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 21 | $255,385 |
| Long term medical supply or device loan | 11 | $11,973 |
| Space rental or facility fees (teaching hospital only) | 4 | $2,784 |
| Education | 1 | $2,000 |
| Grant | 1 | $750 |
| Debt forgiveness | 2 | $585 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | AngioDynamics, Inc. | $1,400 | Long term medical supply or device loan | In-kind items and services | Celerity Device, Vascular Access | 2024 | |
| 2024-12-31 | AngioDynamics, Inc. | $1,400 | Long term medical supply or device loan | In-kind items and services | Celerity Device, Vascular Access | 2024 | |
| 2024-12-31 | AngioDynamics, Inc. | $1,400 | Long term medical supply or device loan | In-kind items and services | Celerity Device, Vascular Access | 2024 | |
| 2024-12-31 | Stryker Corporation | $568 | Long term medical supply or device loan | In-kind items and services | SDC4K Device, ENDOSCOPY | 2024 | |
| 2024-12-31 | Stryker Corporation | $494 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $90 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-25 | Smith+Nephew, Inc. | $51 | Long term medical supply or device loan | In-kind items and services | DYONICS POWERMINI Device, Enabling Technology | 2024 | |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $18,011 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEM | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $2,501 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEM | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $1,650 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEM | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $1,548 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEM | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $1,184 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEM | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEM | 2024 |
| 2024-11-20 | Surmodics, Inc. | $1,628 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-11-14 | Abbott Laboratories | $534 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMPLATZER PICCOLO Device, Structural Heart | 2024 | |
| 2024-10-23 | Medtronic, Inc. | $1,958 | Long term medical supply or device loan | In-kind items and services | SYMPLICITY G3 Device, Renal Denervation System | 2024 | |
| 2024-09-30 | Merck Sharp & Dohme LLC | $33,210 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 mRNA-4157 | 2024 |
| 2024-09-28 | Siemens Medical Solutions USA, Inc. | $750 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-09-10 | Janssen Biotech, Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TECVAYLI Biological, Oncology | 2024 | |
| 2024-09-05 | Regeneron Pharmaceuticals, Inc. | $6,351 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEM | 2024 |
| 2024-09-05 | Regeneron Pharmaceuticals, Inc. | $5,606 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEM | 2024 |
| 2024-09-05 | Regeneron Pharmaceuticals, Inc. | $3,900 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEM | 2024 |
| 2024-09-05 | Regeneron Pharmaceuticals, Inc. | $3,558 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEM | 2024 |
| 2024-09-05 | Regeneron Pharmaceuticals, Inc. | $163 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEM | 2024 |
| 2024-08-23 | AstraZeneca Pharmaceuticals LP | $18,297 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination with Tremelimumab Lenv | 2024 |
| 2024-08-23 | AstraZeneca Pharmaceuticals LP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2024 | |
| 2024-08-20 | Penumbra, Inc. | $2,000 | Education | Cash or cash equivalent | 2024 | ||
| 2024-08-01 | Aveo Pharmaceuticals, Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2024 | |
| 2024-07-05 | ABBVIE INC. | $24,043 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-05-22 | Surmodics, Inc. | $157 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-05-22 | Surmodics, Inc. | $157 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-03-07 | ABBVIE INC. | $24,043 | Research payment | Cash or cash equivalent | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel | 2024 | |
| 2024-02-16 | AstraZeneca UK Limited | $49,639 | Research payment | Cash or cash equivalent | Truqap Drug, Oncology | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetax | 2024 |
| 2024-02-14 | AngioDynamics, Inc. | $99 | Long term medical supply or device loan | In-kind items and services | C3 WAVE SYSTEM Device, Vascular Access | 2024 | |
| 2024-02-14 | AngioDynamics, Inc. | $99 | Long term medical supply or device loan | In-kind items and services | C3 WAVE SYSTEM Device, Vascular Access | 2024 | |
| 2024-02-14 | AngioDynamics, Inc. | $99 | Long term medical supply or device loan | In-kind items and services | C3 WAVE SYSTEM Device, Vascular Access | 2024 | |
| 2024-01-05 | AstraZeneca Pharmaceuticals LP | $14,500 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2024 |
| 2024-01-04 | Novartis Pharmaceuticals Corporation | $44,237 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for th | 2024 | |
| 2024-01-01 | Smith+Nephew, Inc. | $2,447 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Resection | 2024 | |
| 2024-01-01 | Smith+Nephew, Inc. | $2,447 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Resection | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Yuma, AZ, county Yuma County, AZ, state Arizona; placed by its city name.
| Measure | Place (city or town) Yuma, AZ | County Yuma County, AZ | State Arizona |
|---|---|---|---|
| Population B01003 | 100,139 | 211,741 | 7,378,838 |
| Population, 2020 census P1 | 95,548 | 203,881 | 7,151,502 |
| Median age B01002 | 33.1 | 36.1 | 39.0 |
| Under 18 B01001 | 25.5% | 24.6% | 21.6% |
| 65 and over B01001 | 17.6% | 20.7% | 18.9% |
| Households B11001 | 39,110 | 79,341 | 2,856,081 |
| Foreign born B05002 | 19.5% | 25.1% | 13.0% |
| Median household income B19013 | $65,482 | $62,876 | $79,964 |
| Median family income B19113 | $73,504 | $71,136 | $95,980 |
| Per capita income B19301 | $33,951 | $30,204 | $42,503 |
| Poverty rate B17001 | 15.5% | 15.6% | 12.5% |
| Unemployment rate B23025 | 6.3% | 6.9% | 5.1% |
| Civilian labor force B23025 | 42,858 | 83,296 | 3,598,840 |
| Mean commute (minutes) B08013 | 18.4 | 21.3 | 25.4 |
| Bachelor's degree or higher B15003 | 20.9% | 16.8% | 33.3% |
| Housing units B25001 | 44,663 | 95,200 | 3,192,839 |
| Owner-occupied B25003 | 66.8% | 71.0% | 67.4% |
| Renters B25003 | 33.2% | 29.0% | 32.6% |
| Median home value B25077 | $230,000 | $217,800 | $394,500 |
| Median gross rent B25064 | $1,114 | $993 | $1,543 |
| White, not Hispanic B03002 | 31.2% | 29.0% | 52.6% |
| Black B03002 | 1.9% | 1.5% | 4.4% |
| Hispanic or Latino B03002 | 60.8% | 64.9% | 31.4% |
| Asian B03002 | 1.7% | 1.0% | 3.5% |
| American Indian and Alaska Native B03002 | 0.7% | 0.8% | 3.2% |
Economy now FRED unemployment 4.9% in Sep 2026 (4.4% a year earlier); per capita personal income $68,373 in 2025, up 31% in five years (+5.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Yuma, AZ.
Comments